8-K: Vanda Pharmaceuticals Reports Mixed Q2 2025 Results with Strong Fanapt Growth Amid Increased Net Loss

Vanda Pharmaceuticals announced second quarter 2025 financial results, showing a 27% increase in Fanapt sales and progress in its pipeline with two NDA acceptances, but also reported a significantly higher net loss and decreased sales for HETLIOZ and PONVORY.

Summary

• Total net product sales for the second quarter of 2025 were $52.6 million, a 4% increase compared to $50.5 million in the second quarter of 2024.
• Fanapt net product sales increased by 27% to $29.3 million in Q2 2025, up from $23.2 million in Q2 2024.
• HETLIOZ net product sales decreased by 13% to $16.2 million in Q2 2025, down from $18.7 million in Q2 2024.
• PONVORY net product sales decreased by 18% to $7.1 million in Q2 2025, down from $8.6 million in Q2 2024.
• Net loss for the second quarter of 2025 was $27.2 million, a significant increase from a net loss of $4.5 million in the second quarter of 2024.
• Diluted net loss per share was $0.46 in Q2 2025, compared to $0.08 in Q2 2024.
• Cash, cash equivalents, and marketable securities stood at $325.6 million as of June 30, 2025, representing a decrease of $15.4 million from March 31, 2025, and a $49.1 million decrease from December 31, 2024.
• For the first six months of 2025, total net product sales were $102.6 million, a 5% increase from $97.9 million in the first six months of 2024.
• Net loss for the first six months of 2025 was $56.7 million, compared to $8.7 million in the first six months of 2024.
• The company reiterated its full-year 2025 financial guidance, expecting total revenues of $210 million to $250 million and year-end cash of $280 million to $320 million.
• Fanapt total prescriptions (TRx) increased by approximately 24% in Q2 2025 compared to Q2 2024, supported by an ongoing direct-to-consumer brand awareness campaign.
• The New Drug Application (NDA) for Bysanti (milsaperidone) for bipolar I disorder and schizophrenia has been accepted for filing by the FDA, with a PDUFA target action date of February 21, 2026.
• The NDA for Tradipitant for motion sickness has been accepted for filing by the FDA, with a PDUFA target action date of December 30, 2025.
• A Phase III clinical study for Bysanti as an adjunctive treatment for major depressive disorder (MDD) is currently enrolling patients, with results anticipated in 2026.
• The Biologics License Application (BLA) for Imsidolimab in generalized pustular psoriasis (GPP) is expected to be submitted to the FDA in 2025.
• The company submitted a public response to the U.S. Department of Health and Human Services (HHS) Request for Information (RFI) on July 14, 2025, proposing the repeal of unlawful regulations that delay drug approval and 1990s-era guidance mandating lethal animal testing.

Sentiment

Score: 4

Explanation: The sentiment is mixed to slightly negative. While Fanapt sales showed strong growth and pipeline advancements are notable with two NDA acceptances and a BLA submission expected, the significant increase in net loss and the continued cash burn are considerable concerns. The reiteration of guidance provides some stability, but the worsening profitability metrics weigh down the overall sentiment.

Positives

• Fanapt net product sales increased significantly by 27% to $29.3 million in Q2 2025 compared to Q2 2024, driven by a 24% increase in total prescriptions and a direct-to-consumer campaign.
• Total net product sales saw a 4% increase in Q2 2025 and a 5% increase in the first six months of 2025 compared to the respective prior year periods.
• The New Drug Application (NDA) for Bysanti (milsaperidone) for bipolar I disorder and schizophrenia was accepted for filing by the FDA.
• The NDA for Tradipitant for motion sickness was accepted for filing by the FDA.
• The Biologics License Application (BLA) for Imsidolimab in generalized pustular psoriasis (GPP) is expected to be submitted to the FDA in 2025, indicating pipeline advancement.
• A Phase III clinical study for Bysanti in major depressive disorder (MDD) is actively enrolling patients, with results expected in 2026.

Negatives

• Net loss significantly increased to $27.2 million in Q2 2025 from $4.5 million in Q2 2024, and to $56.7 million in the first six months of 2025 from $8.7 million in the first six months of 2024.
• Diluted net loss per share increased to $0.46 in Q2 2025 from $0.08 in Q2 2024.
• HETLIOZ net product sales decreased by 13% in Q2 2025 compared to Q2 2024.
• PONVORY net product sales decreased by 18% in Q2 2025 compared to Q2 2024.
• Cash, cash equivalents, and marketable securities decreased by $15.4 million in Q2 2025 and by $49.1 million in the first six months of 2025.

Risks

• Actual results could differ materially from forward-looking statements due to changes in circumstances and uncertainties.
• Assumptions regarding the strength of the U.S. business may not be realized.
• Ability to complete clinical development of products in the pipeline and obtain regulatory approval is not assured.
• The FDA may not complete its reviews of, or reach decisions with respect to, the NDAs for Bysanti and Tradipitant by their respective PDUFA target action dates.
• Ability to complete and submit the BLA for Imsidolimab in 2025 is not guaranteed.
• Ability to increase market awareness of Fanapt and continue to drive Fanapt revenue growth may face challenges.
• Ability to obtain FDA approval of Bysanti and Tradipitant and successfully execute their commercial launches is uncertain.
• Ability to complete the Phase III clinical study for Bysanti for MDD and receive results in 2026 is subject to risks.

Future Outlook

The company reiterated its full-year 2025 financial guidance, expecting total revenues between $210 million and $250 million and year-end cash between $280 million and $320 million. Significant regulatory and clinical milestones are anticipated, including PDUFA target action dates for Bysanti (February 21, 2026) and Tradipitant (December 30, 2025), expected submission of Imsidolimab BLA in 2025, and Phase III results for Bysanti in MDD in 2026. The company expects the accelerated growth trend of Fanapt revenue to continue in the coming quarters.

Management Comments

• "We have witnessed accelerated growth of Fanapt revenue coinciding with the expansion of our sales efforts alongside a broad direct to consumer brand awareness campaign and we expect this trend to continue in the coming quarters."
• "Significant regulatory and clinical milestones are expected in the coming months which have the potential to strengthen our commercial portfolio and advance our deep clinical pipeline."

Industry Context

The filing does not provide specific analysis of how these results relate to broader industry trends or competitors, focusing primarily on the company's internal performance and pipeline progress within the biopharmaceutical sector.

Comparison to Industry Standards

• The filing does not provide specific comparisons to global benchmarks or detailed results of comparable companies or projects within the industry.

Stakeholder Impact

• Shareholders may experience volatility due to mixed financial results, with strong product growth offset by increased losses and cash burn, impacting short-term profitability but potentially benefiting from long-term pipeline advancements.
• Patients could benefit from potential new therapies if Bysanti, Tradipitant, and Imsidolimab receive regulatory approvals.
• Employees' roles and the company's strategic direction are tied to the success of commercial products and pipeline development.

Next Steps

• FDA review and decision on Bysanti NDA for bipolar I disorder and schizophrenia by February 21, 2026 (PDUFA target action date).
• FDA review and decision on Tradipitant NDA for motion sickness by December 30, 2025 (PDUFA target action date).
• Submission of Imsidolimab Biologics License Application (BLA) in generalized pustular psoriasis (GPP) to the FDA in 2025.
• Continued enrollment in the Bysanti Phase III clinical study for major depressive disorder (MDD), with results expected in 2026.
• Continued expansion of sales efforts and direct-to-consumer brand awareness campaigns for Fanapt and PONVORY.
• Ongoing efforts to advocate for regulatory changes with the U.S. Department of Health and Human Services (HHS) regarding drug approval processes and animal testing.

Key Dates

Recommendation

The recommendation is 'hold' for a seasoned investor. While Fanapt's strong sales growth and the significant progress in the clinical pipeline (two NDA acceptances, one BLA expected) present long-term upside potential, the substantial increase in net loss and the ongoing cash burn are immediate concerns. The reiteration of full-year guidance suggests management believes the company is on track, but investors should monitor future profitability trends and the outcomes of the regulatory reviews for Bysanti and Tradipitant before making a more definitive investment decision.

Keywords

Biopharmaceutical, Pharmaceuticals, Schizophrenia, Bipolar I Disorder, Motion Sickness, Generalized Pustular Psoriasis, Major Depressive Disorder, Fanapt, HETLIOZ, PONVORY, Bysanti, Tradipitant, Imsidolimab, FDA, NDA, BLA, PDUFA, Clinical Trials, Drug Development, Financial Results